English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

A ruthenium(II) complex coordinated by cordycepin, [Cor‑Ru(II)], was synthesized for investigation as a potential novel candidate for cancer therapy. The antitumor activity of Cor‑Ru(II) was investigated by MTT and flow cytometry (FCM) assays. The results showed that Cor‑Ru(II) significantly inhibited the proliferation of Bel‑7402 human hepatoma cells and delayed cell cycle progression. Subsequent experiments using FCM and western blot analysis indicated that Cor‑Ru(II) induced cell apoptosis via suppression of bcl‑2 expression and stimulation of p53 expression. Cor‑Ru(II) was shown to interfere with the synthesis of DNA. This was confirmed by the in vitro binding to DNA in the groove binding mode (Kb=4.22(±0.2)x10(5) M(‑1)). Thus, Cor‑Ru(II) appears to act as an effective antitumor agent in vitro.

Apoptosis of Bel-7402 human hepatoma cells induced by a ruthenium(II) complex coordinated by cordycepin through the p53 pathway